STEPHEN D. SMITH M.D.
5/17/12
OFFICE:
University of Kansas
Medical Center
Department of Pediatrics
3901 Rainbow Blvd
Kansas City, Kansas 66160
Phone: (913) 588-6340
Fax: (913) 588-2245
E-mail: ssmith8@kumc.edu
Education:
Dates
8/63-5/67
Institution
Creighton University
Omaha, NE
Degree
B.S.
8/67-5/71
Creighton University
School of Medicine
Omaha, NE
M.D.
Post Doctoral Training:
Dates
6/71-6/72
Institution
University of Kansas
Medical Center
Kansas City, KS
Specialty
Intern Pediatrics
6/72-6/73
University of Kansas
Medical Center
Kansas City
Resident Pediatrics
7/75-6/77
University of Kansas
Medical Center
Kansas City, KS
Fellow, Pediatric
Hematology/Oncology
U.S. Army
Vint Hill Farm Station
Vint Hill, Virginia
Military Service:
7/73-6/75
Licensure:
Year
Number
State
8/30/71
12/9/77
7/6/82
7/1/89
5/16/03
12327
17361
G48085
036-079523
2003010756
Nebraska
Kansas
California
Illinois
Missouri
Board Certification:
Date of Certification
Name of Board
1971
State of Healing Arts, Nebraska
1972
Diplomat: National Board of Medical
Examiners
7/1/77
Diplomat: American Board of Pediatrics
10/10/80
American Board of Pediatrics, Sub-Board
of Pediatric Hematology/Oncology
Professional Positions Held:
Month and Year
Position & Institution
7/77-6/82
Assistant Professor of Pediatrics and
Pharmacology
University of Kansas Medical Center
Kansas City, KS
7/82-6/89
Associate Professor of Pediatrics
Stanford University School of Medicine
Stanford, CA
7/89-6/94
Associate Professor of Pediatrics and Medicine
University of Chicago Medical Center
Chicago, IL
7/94-6/97
Professor of Pediatrics and Medicine
University of Chicago Medical Center
Chicago, IL
7/97- 6/06
Professor of Pediatrics
University of Kansas Medical Center
2
Kansas City, KS
7/06 – 6/11
Professor of Pediatrics
University of Illinois,
College of Medicine at Peoria, Peoria, IL
7/11- present
Professor of Pediatrics
University of Kansas Medical Center
Kansas City, KS
Teaching Experience:
All areas of pediatrics hematology/oncology with a focus on leukemia, solid tumors, coagulation,
blood banking and bone marrow failure. Since 2011, I have been teaching pediatric
hematology/oncology to the third year medical students and residents.
Didactic:
Academic
Year
2006 -11
Instruction
Course
Title
Type
Pediatrics Pediatrics
Residency
Student
No.
Type
Hours
1 hours / wk
12-15 Residents
Non didactic:
Clinical
Year
Hours
Student
No.
2006-2011
10- 20 hours/week
6-9
Type
Length of Service
Medical Students
& Residents
4 Months / year
Inpatient ward service with patient care, teaching and night call for 4 months each year.
Committee Service: Give dates of service and administrative positions held
Academic: PI, Children’s Oncology Group (2006-2011)
Hospital: Member, KUMC Institutional Review Board (2011-)
3
Funded Research Activity;
Past Grant Support:
1.
Mid-America Cancer Center Program
In vitro culture and sensitivity of normal and malignant bone marrow cells.
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 20%
3/77 - 6/78
Annual Direct Costs - $3,000
2.
NIH Bio-Medical Research Support Grant, 5501-RR-5373, Research
Committee University of Kansas Medical Center
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 20%
Colony forming potential of malignant lymphoblasts from the bone marrow
of Children with A.L.L. or N.H.L.
Annual Direct Costs - $1,110
9/1/78 - 3/31/79
3.
Mid-America Cancer Center Program, CA-15080-05
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 20%
Drug sensitivity of malignant lymphoblasts from children with acute
Lymphoblastic leukemia and non-Hodgkin’s lymphoma.
Annual Direct Costs - $2,603
7/1/78 - 6/30/79
4.
Research Committee, Endowment Funds, University of Kansas Medical
Center
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 20%
Differentiation of malignant colony forming cells from non-colony forming
cells in progressive lymphoid malignancies.
Annual Direct Costs - $2,577
12/10/79 - 12/10/80
5.
National Cancer Institute RO1 CA34710
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 33%
Culture, sensitivity of malignant lymphoid colonies.
Annual Direct Costs - $83,951
5/1/80 - 4/30/83
4
6.
American Cancer Society CH-182
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 25%
Differentiation of malignant colony forming cells from non-colony forming
cells in progressive lymphoid malignancies.
Annual Direct Costs - $50,131
7/1/81 - 6/30/82
7.
Leukemia Society of America - Scholar’s Program - 16S-82
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 10%
In vitro culture and drug sensitivity of leukemia cell populations
Annual Direct Costs - $27,000
7/01/83 - 8/31/87
8.
The Council for Tobacco Research - USA, Inc.
Principal Investigator - Gerald R. Crabtree, M.D.
Percent Effort - 5%
Retroviral Insertion and Activation of the IL-2 Gene
Annual Direct Costs: $80,000
1/1/86 - 12/31/88
9.
NIH Research Grant - Cyano-Morpholino Anthracyclines
Principal Investigator - Branimir I. Sikic, M.D.
Percent Effort - 5%
Annual Direct Costs: $96,481
9/1/86 - 8/31/89
10.
NCI PO1 CA 34233-Clinical and Laboratory Studies of the Malignant
Lymphomas
Principal Investigator - Saul A. Rosenberg, M.D.
4/1/86 - 3/31/91
Annual Direct Costs - $1,447,044
Project 4 - CTL Target and Effector Antigens in Non-Hodgkin’s
Lymphoma
Project Investigator - Alan Krensky, M.D.
Co-investigator - 10%
Annual Direct Costs -$71,172
4/1/86-3/31/91
Project 5 - Patterns of Spread of Lymphoid Malignancies
Project Investigator - Jeffrey Sklar, M.D.
Co-investigator - 5%
Annual Direct Costs - $118,108
4/1/86-3/31/91
5
11.
NIH Research Grant Application CA 42106
Principal Investigator - Stephen D. Smith, M.D.
Percent Effort - 20%
Characterization of lymphoblast peptide receptors
Annual Direct Costs - $106,389
9/1/87 - 8/31/90
12.
NIH Research Grant Application
Principal Investigator - Branimir I. Sikic, M.D.
Percent Effort - 10%
Multi-drug resistance in human cancer
Annual Direct Costs - $125,430
12/1/87 - 11/30/90
13.
NIH Research Grant Application
Principal Investigator - Jeffrey Sklar, M.D., Ph.D.
Percent Effort - 5%
Genetic studies of human B-cell cancers
Annual Direct Costs - $194, 431
4/1/88 - 3/31/93
14.
National Institutes of Health
Principal Investigator - Michael P. Link, M.D.
Percent of Effort - 2.5%
Research Grant - Pediatric Oncology Group
Annual Direct Costs - $48,790
1/1/87 - 12/31/90
15.
NCI PO1 CA 40046
Principal Investigator - Janet Rowley, M.D.
Percent Effort - 10%
Etiology of Treatment-Induced Secondary Leukemia
Annual Direct Costs - $550,000
12/1/91 - 11/30/96
16.
Grant from Ronald McDonald Children’s Charities
Principal Investigator: Stephen D. Smith, M.D.
Percent Effort - 10%
Placental Blood Bank
Annual Direct Costs - $67,238
11/1/95 - 10/31/96
6
17.
Grant from B. Meltzer Fund for Pediatric Cancer Research
Principal Investigator: Stephen D. Smith, M.D.
Richard L. Moldwin, M.D., Ph.D., became P.I. on 7/1/97
Percent Effort - 10%
Biology of Acute Lymphoblastic Leukemia
Annual Direct Costs - $50,000
1/1/91 - 6/30/98
18.
Grant from Bear Necessities Pediatric Cancer Foundation
Principal Investigator: Stephen D. Smith, M.D.
Richard L. Moldwin, M.D., Ph.D., became P.I. on 7/1/97
Percent Effort - 10%
Cord Blood Banking and Research
Annual Direct Costs - $35,000
7/1/95 - 6/30/98
19.
Grant from Blood Systems Foundation
Principal Investigator: Stephen D. Smith, M.D.
Richard L. Moldwin, M.D., Ph.D., became P.I. on
7/1/97
Percent Effort - 10%
Placental Blood Banking and Transplantation
Annual Direct Costs - $100,000
9/1/95 - 8/31/98
20.
National Cancer Institute U10 CA 98543
Principal Investigator: Robert Trueworthy, M.D.
S D Smith (co-investigator)
Children’s Oncology Group, Chair’s Grant,
1/1/03-12/31/08
21.
National Childhood Cancer Foundation
The Children's Oncology Group
Master Subcontract
Principal Investigator: Stephen Smith, M.D.
Dr de Alarcon became PI on 7/1/11
3/1/08 – 2/28/14 (I left UICOMP 6/11)
7
Professional Society Memberships:
Year
Organization (including offices held)
1977
1979
1980
1980
1981
American Academy of Pediatrics
Sigma Xi
Society for Pediatric Research
American Society of Hematology
American Society of Pediatric
Hematology/Oncology
American Society of Clinical Oncology
American Association for Cancer Research
American Pediatric Society
1984
1984
2005
Honors, Awards, Recognition:
Year
Award
1978
1978
1982
1986
2001
2002
2002
2003
2003
2004
2004
2004
2004
2005
2006
American Cancer Society Junior Faculty Clinical Fellowship
Pediatric Department “Teacher of the Year” Award
Scholar of the Leukemia Society of America
Stohlman Memorial Scholar Award, Leukemia Society of America
Student Voice Award, Excellence in Teaching
Pediatric Department “Teacher of the Year” Award
Student voice Award, Excellence in Teaching
Finalist, University of Kansas School of Medicine Rainbow Award
Student Voice Award, Excellence in Teaching
Student Voice Award, Excellence in Teaching
Bohan Teaching Award ($5,000)
W. T. Kemper Fellowship for Teaching Excellence ($5,000)
Medical School Marshal at Graduation
Student Voice Award, Excellence in Teaching
Student Voice Award, Excellence in Teaching
8
BIBLIOGRAPHY
REFEREED PUBLICATIONS: (Underline Senior Author)
TOTAL 91
1.
Khoo HB, Cho CT, Smith SD and Dudding BA: Cervical lymphadenitis due to candida
albicans infection. J Pediatr 86:812-813, 1975.
2.
Smith SD and Cho CT: Cytomegalovirus in sudden infant death syndrome (SIDS).
JAMA 233:861, 1975.
3.
Smith SD, Cho CT, Brahmacupta N and Lenahan MF: Pulmonary involvement
associated with cytomegalovirus infection in children. Arch Dis Child 52:441- 446, 1977.
4.
Smith SD, Uyeki EM and Lowman JT: Colony formation in vitro by leukemic cells in
acute lymphoblastic leukemia. Blood 52:712-718, 1978.
5.
Smith SD, Rosen D, Trueworthy RC and Lowman JT: A reliable method for evaluating
drug compliance in children with cancer. Cancer 43:169-173, 1979.
6.
Smith SD, Sturgeon JK, Rosen D, Vats TS, Trueworthy R, Cairns N, Klopovich P,
Briscoe K and Lansky S: Total care. Recent advances in the treatment of children with
cancer. J Kans Med Soc 80:113-118, 1979.
7.
Smith SD, and Rosen D: Establishment and characterization of a human null cell
lymphoblastic lymphoma cell line (K-LL-3). Int J Cancer 23:494-503, 1979.
8.
Smith SD, and Sachs L: Differences in the cell proliferation and colony forming ability
of normal human T lymphocytes. Clin Exp Immuno 37:348-351, 1979.
9.
Cairns NU, Clark GM, Smith SD, and Lansky SB: Adaptation of siblings to childhood
malignancy. J Pediatr 95:484-351, 1979.
10.
Smith SD: Update on sarcoma in children. Cancer Control for the Professional. 6:33-34,
1979.Smith SD, Lindsley C, and Abdou NI: Suppressor cell-mediated leukopenia and Tcell dysfunction in Nezelof’s Syndrome: Clin Immunol Immunopathol 197:406-414,
1980.
11.
Smith SD, Cairns NU, Sturgeon JK and Lansky SB: Poor drug compliance in an
adolescent with leukemia. Am J Pediatr Hematol/Oncol 3:297-300, 1981.
12.
Vats TS, Mehta P, Trueworthy RC, Smith SD and Klopovich P: Vindesine and
prednisone for remission induction in children with acute lymphocytic leukemia. Cancer
47:2789-1792, 1981.
13.
Smith SD, Wood GW, Fried P and Lowman JT: In vitro growth of lymphoma colonies
from children with non-Hodgkin’s lymphoma. Cancer 48:2612-2623, 1981.
14.
Smith SD: Advances in the pharmacology of cancer chemotherapy. Pediatr Clin North
Am 28:145-160, 1981.
9
15.
Smith SD, Trueworthy RC, Kisker SE, Noller LG, and Lowman JT: In vitro sensitivity of
normal granulocytic and lymphoma colonies to vinca alkaloids. Cancer 53:417-422,
1983.
16.
Roper M, Crist WM, Metzger R, Ragab AH, Smith, S, Starling K, Pullen J, Leventhal B,
Bartolucci AA and Cooper MD: Monoclonal antibody characterization of surface
antigens in childhood T-cell lymphoid malignancies. Blood 61:830-837, 1983.
17.
Lansky SB, Smith SD, Cairns NU and Cairns GF Jr: Psychological correlates of
compliance. J Pediatr Hematol/Oncol 5:87-92, 1983.
18.
Wittek AE, Cohen PS, Arvin AM, Smith SD, Koropchak CM and DeClercq E: Effects of
(E)-5(-bromovinyl)-2’-deoxyuridine on proliferation of human fibroblasts, peripheral
blood mononuclear cells and granulocyte-monocyte progenitor cells in vitro . Antimicro
Agents and Chemother 24:803-806, 1983.
19.
Smith SD, Kisker S, Bush L and Trueworthy RC: Utilization of a human tumor cloning
system to monitor for bone marrow involvement in children with non-Hodgkin’s
lymphoma. Cancer 53:1724-1729, 1984.
20.
Smith SD, Trueworthy RC, Klopovich PM, Vats TS and Snodgrass W: Management of
children with isolated testicular leukemia. Cancer 54:2854-2858, 1984.
21.
Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP and Glader BE: Monoclonal
antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell
lines. Cancer Research 44:5657-5660, 1984.
22.
Hecht F, Morgan R, Kaiser-McCaw Hecht B and Smith SD: Common region on
chromosome 14 in T-cell leukemia and lymphoma. Science 226:1445-1447, 1984.
23.
Cohen PS and Smith SD: In vitro and in vivo chemotherapy screening of the divalent
cations chelator 1, 10-orthophenanthroline. Cancer Chemother Pharmacol 15:6-10, 1985.
24.
Wu N, Foung SK, Hoopes P, Lizak G and Smith SD: Microwave heat-induced
hemolysis. Clin Pediatr 24:645, 1985.
25.
Baer R, Chen K-C, Smith SD and Rabbitts TH: Fusion of an immunoglobulin variable
gene and a T-cell receptor constant gene in the chromosome 14 inversion associated with
T-cell tumors. Cell 43:705-713, 1985.
26.
Smith SD, Morgan R, Link MP, McFall P and Hecht F: Cytogenetic and
immunophenotypic analysis of cell lines established from patients with T-cell
leukemia/lymphoma. Blood 67:650-656, 1986.
27.
Lee PDK, Rosenfeld RG, Hintz RL and Smith SD: Characterization of insulin, insulinlike growth factors I and II, and growth hormone receptors on human leukemic
lymphoblasts. J Clin Endocrinol Metab 62:28-35, 1986.
28.
Denny CT, Yoshikai Y, Mak TW, Smith SD, Hollis GF and Kirsch IR: A chromosome
14 inversion in a T cell lymphoma is caused by site-specific recombination between
immunoglobulin and T cell receptor loci. Nature 320:549-551, 1986.
10
29.
Cleary ML, Smith SD and Sklar J: Cloning and Structural Analysis of cDNAs for bcl-2
and a Hybrid bcl-2/Immunoglobulin Transcript Resulting from the t(14;18)
Translocation. Cell 47:19-28, 1986.
30.
Denny CT, Hollis GF, Hecht F, Morgan R, Link MP, Smith SD and Kirsch IR: A
common mechanism of chromosomal inversion in B and T cell tumors: Relevance to
lymphocyte development. Science 234:197-200, 1986.
31.
Westbrook CA, Rubin CM, Le Beau MM, Kaminer LS, Smith SD, Rowley JD and Diaz
MO: Molecular analysis of TCRB and ABL in a t(7;9)-containing cell line (SUP-T3)
from a human T-cell leukemia. Proc Natl Acad Sci 84:251-255, 1987.
32.
Barletta C. Pelicci P-G, Kenyon LC, Smith SD and Dalla-Favera R: Relationship
between the c- myb locus and the 6q-chromosomal aberration in leukemias and
lymphomas. Science 235:1064-1067, 1987.
33.
Smith SD, Morgan R, Galili N, Amylon MD, Link MP, Hecht F, Sklar J Glader BE.
Establishment and characterization of a common acute lymphoblastic leukemia cell line
with a deletion of chromosome 3 band q26. 1987 Cancer Res. 1987 March
15;47(6):1652-6.
34.
Reynolds TC, Smith SD and Sklar J: Analysis of DNA surrounding the breakpoint of a
chromosomal translocation involving the beta T cell receptor gene in human
lymphoblastic neoplasms. Cell 50:107-117, 1987.
35.
Clayberger C, Wright A, Medeiros LJ, Koller TD, Link MP, Smith SD, Warnke RA and
Krensky AM: Absence of cell surface LFA-1 as a mechanism of escape from immune
surveillance. Lancet II:533-536, 1987.
36.
Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J,
Smith SD and Civin CI. Elimination of clonogenic malignant human T cells using
monoclonal antibodies in combination of 2’-deoxycoformicin. J Clin Oncol 5:1900-1911,
1987.
37.
Picker LJ, Brenner MB, Weiss LM, Smith SD and Warnke RA. Discordant Expression of
CD3 and T-Cell Receptor Beta-Chain Antigens in T-Lineage Lymphomas. Am J Pathol
129:434-440, 1987.
38.
Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD and Croce
CM. A new fused transcript in Philadelphia chromosome positive acute lymphocytic
leukemia. Nature 330:386-388, 1987.
39.
Smith SD, Morgan R, Gemmell R, Amylon MD, Link MP, Linker C, Hecht BK, Warnke
R, Glader BE and Hecht F. Clinical and biologic characterization of T cell neoplasias
with rearrangements of chromosome 7 band q34. Blood 71: 395-402, 1988.
40.
Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist
W, Rovera G, Smith SD and Witte ON. Expression of a distinctive BCR-ABL oncogene
in Ph1 - positive acute lymphocytic leukemia (ALL). Science 239:775-777, 1988.
11
41.
Cleary ML, Mellentin JD, Spies J and Smith SD. Chromosomal translocation involving
the beta T cell receptor gene in acute leukemia. J Exp Med 167:682, 1988.
42.
Carroll WL, Link MP, Cleary ML, Bologna S, Carswell C, Amylon MD, Smith SD and
Levy R. Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic
leukemia. Blood 71:1068-1073, 1988.
43.
Naumovski L, Morgan R, Hecht F, Link MP, Glader BE and Smith SD. Philadelphia
chromosome positive acute lymphoblastic leukemia cell lines without bcr rearrangement.
Cancer Research 48:2876-2879, 1988.
44.
Beckman RA, McFall PJ, Sikic BI and Smith SD. Doxorubicin and the alkylating
anthracycline 3’-deamino3’-(3-cyano-4-morpholinyl) doxorubicin: Comparative in vitro
potency against leukemic and bone marrow cells. J Natl Cancer Inst 80:361-365, 1988.
45.
Rubin CM, Carrino JJ, Dickler MN, Leibowitz D, Smith SD and Westbrook CA.
Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive
acute lymphoblastic leukemia. Proc Natl Acad Sci USA 85:2795-2799, 1988.
46.
Diaz MO, Zieman S, Le Beau MM, Pitha P, Smith SD, Chilcote RR and Rowley JD.
Homozygous deletion of the alpha and beta-1 interferon genes in human leukemia and
derived cell lines. Proc Natl Acad Sci USA 85”5259-5263, 1988.
47.
Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON and McCormick
FP. Diagnosis of chronic myeloid leukemia and acute lymphoblastic leukemia by
detection of l leukemia-specific mRNA sequence amplified in vitro. Proc Natl Acad Sci
85:5698-5702, 1988.
48.
Tycko B, Reynolds TC, Smith SD and Sklar J: Consistent breakage between consensus
recombinase heptamers of chromosome 9 DNA in a recurrent chromosomal translocation
of human T-cell leukemia. J Exp Med 169: 369-377, 1989.
49.
Smith SD, McFall P, Morgan R, Link M, Hecht F, Cleary M and Sklar J: Long-Term
Growth of Malignant Thymocytes In Vitro. Blood 73:2182-2187, 1989.
50.
Tycko B, Palmer JD, Link MP, Smith SD and Sklar J: Polymerase chain reaction
amplication of rearranged antigen receptor genes using junction-specific
oligonucleotides: Possible application for detection of minimal residual disease in acute
lymphoblastic leukemia. Cancer Cells, Cold Spring Harbor 77:45-52, 1989.
51.
Wright A, Lee JE, Link MP, Smith SD Carroll W, Levy R, Clayberger C and Krensky
AM: Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell
receptor delta chain. J Exp Med 169:369-377, 1989.
52.
Morgan R, Smith SD, Hecht BK, Christy V, Mellentin JD, Warnke R and Cleary ML:
Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)
(p23;q35) common to malignancies with features of so-called malignant histiocytosis.
Blood 73:2155-2164, 1989.
12
53.
Mellentin JD, Smith SD and Cleary ML: Lyl-1, a novel gene altered by chromosomal
translocation in T-cell leukemia, codes for a protein with a helix-loop-helix DNA-binding
motif. Cell 58:77-83, 1989.
54.
Naumovski L, Utz PJ, Bergstrom SK, Morgan R, Molina A, Toole JJ, Glader BE, McFall
P, Weiss LM, Warnke R and Smith SD: SUP-HD1: A new Hodgkin’s disease-derived
cell line which produces interferon gamma and has features of both B- and Tlymphocytes. Blood 74:2733-2742, 1989.
55.
Mellentin JD, Murre C, Donlon TA, McCaw PS, Smith SD, Carroll AJ, McDonald ME,
Baltimore D, and Cleary ML: The gene for enhancer binding protein E12/E47 lies at the
t(1;19) breakpoint in leukemias. Science 246:379-382, 1989.
56.
Bertness VL, Felix CA, McBride WO, Morgan R, Smith SD, Sandberg A, and Kirsch IR:
Characterization of the breakpoint of a t(14;14) (q11.2;q32) from the leukemic cells of a
patient with T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 44:47-54,
1990.
57.
Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, and Cleary ML.
Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that
codes for a potential chimeric transcription factor. Cell 60:535-545, 1990.
58.
Smith SD, Rubin CM, Horvath A, and Nachman J: Non-Hodgkin’s lymphoma in
children. Seminars in Oncol 17:113-119, 1990.
59.
Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, and Sondel PM: Specific
recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D
restricted unique determinants on leukemic cells that are crossreactive with determinants
present on unrelated non-leukemic cells. Blood 75:2005-2016, 1990.
60.
Mellentin JD, Nourse J, Hunger SP, Smith SD, and Cleary ML: Molecular analysis of the
t(1;19) breakpoint cluster region in pre-B cell acute lymphoblastic leukemias. Genes,
Chromosomes and Cancer 2:239-247, 1990.
61.
Saltman DL, Melletin JD, Smith SD, and Cleary ML: Mapping of translocation
breakpoints on the short arm of chromosome 19 in acute leukemias by in situ
hybridzation. Genes, Chromosomes and Cancer 2:259-265, 1990.
62.
Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, and Arvin AM: Lack of
transmission of the live attenuated varicella vaccine virus to immunocompromised
children after immunization of their siblings. Pediatrics 87:166-170, 1991.
63.
Neely EK, Smith SD, and Rosenfeld RG: Human leukemic T and B lymphoblasts
produce insulin-like growth factor binding protein 2 and 4. Acta Endocrinologica
124:707-714, 1991.
64.
Buchanan GR, Boyett JM, Pollack BH, Smith SD, Yanofsky RA, Ghim T, Wharam MD,
Crist WM, Vietti TJ, Johnson W, and Rivera GK: Improved treatment results in boys
with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic
leukemia: A Pediatric Oncology Group Study. Cancer 68:48-55, 1991.
13
65.
Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD and Sklar J: TAN-1,
the human homologue of the drosophila Notch gene, is broken by chromosomal
translocations in human lymphoblastic neoplasms. Cell 66:649-661, 1991.
66.
Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A,
Rubinelli P, Smith SD, LeBeau MM, Rowley JD and Diaz MO: Identification of a gene,
MLL, that spans the breakpoint in 11q23 translocations associated with human
leukemias, Proc Natl Acad Sci 88:10735-10739, 1991. Erratum in Proc Natl Acad Sci U
S A 1992 May 1;89:4220.
67.
Tycko B, Smith SD, and Sklar J: Chromosomal translocations joining LCK and TCRB
genes in human T-cell leukemia. J Exp Med 174:867-873, 1991.
68.
Wofford MM, Smith SD, Shuster JJ, Johnson W, Buchanan GR, Wharam MD, Ritchey
AK, Rosen D, Haggard ME, Golembe BL and Rivera GK: Treatment of occult or late
overt testicular relapse in children with acute lymphoblastic leukemia. A Pediatric
Oncology Group Study. J Clin Oncol 10:624-630, 1992.
69.
Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD and Look AT:
Fusion of the leucine zipper gene, HLF, to the E2A gene in human acute B-lineage
leukemia. Science 257:531-534, 1992.
70.
Neely EK Rosenfield RG, Illescas A. and Smith SD. Mitogenic effects of human
recombinant insulin on B-cell precursor acute lymphoblastic leukemia cells. Leukemia
6:1134-1142, 1992.
71.
Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, and Rivera GK: A
treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A
Pediatric Oncology Group Study. Blood 81:602-609, 1993.
72.
Winick NJ, Smith SD, Shuster J. Lauer S, Wharam MD, Land V, Buchanan GR and
Rivera G: Treatment of CNS relapse in children with acute lymphoblastic leukemia: A
Pediatric Oncology Group Study. J Clin Oncol 11:271-278, 1993.
73.
Lorenzana AN, Mc Cabe NR, Goodell WR, Zhang LQ, Miley D, Le Beau MM, Goldman
S, and Smith SD: Characterization of a CD34+ cell line established from a child with
large cell cutaneous lymphoma. Cancer 72:931-937, 1993.
74.
Zhang LQ, Downie P, Goodell WR, McCabe NR, Le Beau MM, Morgan R, Sklar J,
Raimondi SC, Miley D, Goldberg A, Lu MM, Montage A and Smith SD: Establishment
of cell lines from B-cell precursor acute lymphoblastic leukemia. Leukemia 7:1865-1874,
1993.
75.
Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD and Sikic BI: Mdr1
gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical
evaluation by four techniques. Leukemia 8:327-335, 1994.
76.
Downie P, Vogelzang NJ, Moldwin RL, Le Beau MM, Anastasi J, Larson RA, Allen RJ,
Meyers SE and Smith SD: Establishment of a leukemia cell line with i(12p) from a
patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer
Research 54:4999-5004, 1994.
14
77.
Brown KE, Green SW, de Mayolo JA, Bellanti JA, Smith SD, Smith TJ and Young NS:
Congenital anemia after transplacental B19 parvovirus infection. The Lancet 343:895-6,
1994.
78.
Stranks G, Height S, Mitchell P, Jasayel D, Yuille MAR, De Lord C, Cluterbuck RD,
Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD,
Miller JL, Catovsky D and Dyer MJS: Deletions and rearrangements of CDKN2 in
lymphoid malignancies. Blood 85:893-901, 1995.
79.
Zhou M, Yeager AM, Smith SD, and Findley HW: Over expression of the MDM2 gene
by childhood acute lymphoblastic leukemia cells expressing the wild-type P53 gene.
Blood 85:1608-1614, 1995.
80.
Zhou M, Gu L, James CD, He J, Yeager AM, Smith SD, and Findley HW: Homozygous
deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with
acute lymphoblastic leukemia. Leukemia 9:1159-1161, 1995.
81.
Jagasia AA, Sher DA, Le Moine PJ, Kim D-H, Moldwin RL, Smith SD, and Diaz MO.
Deletion or lack of expression of CDKN2 (CDK41/MTS1/INK4A) and MTS2 (INK4B)
in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured
primary leukemia cells. Leukemia 10:624-628, 1996.
82.
Davi F, Gocke C, Smith SD, and Sklar J. Stem cell origin and clonal evolution of human
B-lineage acute lymphoblastic leukemia. Blood 88:609-621, 1996.
83.
Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L, Gupta R, Fears S,
Nucifora G, Rowley JD, and Smith SD. TEL-AML1 Translocations with TEL and
CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood 88:785-794, 1996.
84.
Fears S, Vignon C, Bohlander SK, Smith SD, Rowley JD, and Nucifora G. Correlation
between the TEL/AML1 fusion gene and karyotypic abnormalities in children with B-cell
ALL. Genes, Chromosomes and Cancer 17:127-135, 1996.
85.
Suto Y, Sato Y, Smith SD, Rowley JD, and Bohlander SK. A t(6;12)(q23;p13) results in
the fusion of ETV6 to a novel gene, STL, in a B-cell ALL cell line. Genes, Chromosomes
& Cancer 18:254-268, 1997
86.
Giordano L, Moldwin RL, Downie PA, Goldberg A, Gupta R, Allen R, Aithal NH, Kim
DH, Le Moine PJ, and Smith SD. Growth inhibition of B cell precursor acute
lymphoblastic leukemia cells by monocytes: A role for prostaglandin E2. Leukemia
Research 21:925-932, 1997.
87.
Allen RJ, Smith SD, Moldwin RL, Lu MM, Giordano L, Vignon C, Suto Y, Harden A,
Tomek R, Veldman T, Ried T, Larson RA, Le Beau MM, Rowley JD, and Zeleznik-Le
N. Establishment and characterization of a megakaryoblast cell line with amplification of
MLL. Leukemia 12:1119-27, 1998
88.
Posey Y, Valdivia E, Persons DL, Ally S, Smith DL, Pantazis CG, and Smith SD.
Lipoblastoma presenting as a mesenteric mass in an infant. Journal of Pediatric
Hematology/Oncology 20:580-585, 1998.
15
89.
Reems JA, Fujita D, Tyler T, Moldwin R, and Smith SD. Obtaining an accepted
Investigational New Drug (IND) application to operate an umbilical cord blood bank.
Transfusion 39:357-363, 1999.
90.
Al-Rahawan MM, Gray BM, Mitchell CS, Smith SD. Thoracic vertebral osteomyelitis
with paraspinous mass and intraspinal extension: An atypical presentation of cat-scratch
disease. Pediatric Radiology 2011 (DOI) 10.1007/s00247-011-2087-2.
91.
Al-Rahawan MM, Siebert JD, Mitchell CS, Smith SD. Durable complete response to
chemotherapy in an infant with a clival chordoma. Pediatric Blood & Cancer (in press)
LETTERS: (Underline Senior Author)
TOTAL 11
1.
Hecht F, Morgan R, Gemmil RM, Kaiser-McCaw Hecht B, and Smith SD.
Translocations in T-cell leukemia and lymphoma. N Engl J Med 313:758-759,1985.
2.
Morgan R, Hecht BK, Sandberg AA, Hecht F and Smith SD. Constant chromosome 5q35
breakpoint in malignant histiocytosis. N Engl J Med 314:1322, 1986.
3.
Smith SD, Link MP, Trela M, Amylon M, Sklar J, Morgan R and Hecht F. Chromosome
9 abnormalities in childhood T-cell leukemia. N Engl J Med 315:195-196, 1986.
4.
Naumovski L and Smith SD: Current therapy for chronic granulomatous disease. J
Pediatric 114:1066, 1989.
5.
Naumovski L and Smith SD: Origin of Reed-Sternberg cells in Hodgkin’s disease. N Eng
J Med 321:543, 1989.
6.
Naumovski L, Warnke R, and Smith SD: The never-ending controversies in Hodgkin’s
disease. Blood 75:1744, 1990. (Response).
PROCEEDINGS OF MEETINGS
1.
Cohen PS and Smith SD: The sensitivity of human lymphoblastic cell lines and CFU-C to
1,10-Orthophenanthroline. Human Tumor Cloning. Salmon SE and Trent JM (eds.),
Grune & Stratton Inc., New York, pp. 279-288, 1984.
2.
Smith SD, Warnke RA, Shatsky M, Link MP, Cohen PS and Glader BE: Continuous in
vitro growth of T-cell acute lymphoblastic leukemia of childhood (T-ALL) in an hypoxic
environment. Human Tumor Cloning. Salmon SE and Trent JM (eds.), Grune & Stratton
Inc., New York, pp 269-278, 1984.
3.
Rubin, CM, Westbrook CA, Smith SD, Hooberman AL, Colowick A, Geiger TA, Steele
MM and Rowley JD: Philadelphia chromosome-positive acute lymphoblastic leukemia:
Detection of a DNA rearrangement 50-250 kilobases proximal to BCR1. In: Recent
Advances in Leukemia and Lymphoma (UCLA Symposia on Molecular and Cellular
Biology, Vol. 61), New York: Alan R. Liss, pp. 125-131, 1987.
16
4.
Lopez A, Pantazis P, Sitaras N, Smith S, Linker C, Bozdech M, Antoniades H and
Deisseroth A: Regulation of expression of platelet derived growth factor in chronic
myelogenous leukemia cells. In: Recent Advances in Leukemia and Lymphoma (UCLA
Symposia on Molecular and Cellular Biology, Vol. 61), New York: Alan R. Liss, pp.
277-290, 1987.
5.
Rabbits TH, Baer R, Forster A, Lefranc M-P, Stinson MA, Chen K-C and Smith S:
Joining of the human T-cell receptor alpha chain gene with an immunoglobulin gene in a
chromosome 14 inversion (q11;q32) of T-cell leukemia. In: KR Harrap, Connors TA
(eds.): New Avenues in Developmental Cancer Chemotherapy, Academic Press, London,
pp. 485-494, 1987.
BOOKS AND MONOGRAPHS: (Underline Senior Author)
TOTAL 0
NONE
BOOK CHAPTERS: (Underline Senior Author)
TOTAL 3
1.
Smith SD and Rosen D: Hematology Section. Miller HC and Mattioli, L, eds., Clinical
Problems in Pediatrics. Chicago. Yearbook Medical Publishers, 1977.
2.
Findley HW, Johnson HL and Smith SD. T-cell Acute Lymphoblastic Leukemia and
Natural Killer Cells Lines. Human Cell Culture (pages 157-206). Masters, JRW, ed.,
2000, p 157 -206.
3.
Rapoff MA, McGrath AM and Smith SD. Adherence to treatment demands. In: R. Brown
(Ed.), Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease. A
Biopsychosocial Approach. New York: Oxford University Press (2006), p 138-169.
BOOK REVIEWS:
TOTAL 0
NONE
CREATIVE WORKS: (Poetry, compositions, and exhibitions)
Year
1981
Title Description
Section on pediatric drug compliance in
children with cancer. In “When a Child
has Cancer” a film by Lansky SB,
Coordinator, for the American Cancer
Society.
OTHER: (e.g. Notes and Comments)
TOTAL 1
Intended Audience
Health care personnel who care for
children with cancer or serious
chronic diseases.
TOTAL 0
NONE
TOTAL NUMBER OF ALL PUBLICATIONS: 136
17
WORKS IN PROGRESS:
Al-Rahawan MM, Rapkin LB, Mitchell CS, Winek RR and Smith SD. Successful Treatment of a
Child with Renal Medullary Carcinoma with Chemotherapy.
PAPERS PRESENTED AT PROFESSIONAL MEETINGS:
TOTAL 32
SCIENTIFIC PAPERS PRESENTED AT NATIONAL AND INTERNATIONAL
MEETINGS
1.
*Smith SD, Brahmacupta N, Behbehani AM and Cho CT: Clinical and laboratory
experiences in children with cytomegalovirus. J Pediatr 84:243, 1977.
2.
*Smith SD, Trueworthy RC and Lowman JT: Evaluation of compliance in children with
malignancies. Proc Am Assoc Cancer Res 18:243, 1977.
3.
*Vats TS, Smith SD, Trueworthy RC, Klopovich P and Mehta P. Vindesine (eldisine)prednisone in remission induction of late stage acute lymphoblastic leukemia of
childhood. Proc Am Soc Clin Oncol 21:434, 1980.
4.
*Smith SD, Kisker SE, Bush L and Trueworthy RC. In vitro growth of lymphoma
colonies from children with non-Hodgkin’s lymphoma. Stem Cell 1:318, 1981.
5.
*Smith SD, Kisker SE, Bush LM and Trueworthy RC. A new prognostic indicator in
childhood non-Hodgkin’s lymphoma (NHL): in vitro colony forming culture. Pediatr Res
16:215A, 1982.
6.
*Roper M, Crist W, Metzgar R, Ragab A, Smith S, Starling K, Pullen J, Leventhal B,
Bartolucci A, Cooper M. Monoclonal antibody characterization of surface antigens in
childhood T-cell malignancies. International Society of Pediatric Oncology 1982; A7.
(Berne, Switzerland, September 21-25) 1982.
7.
*Smith SD, Shatsky M, Link MP, Warnke RA and Glader BE: Continuous in vitro
growth of T cell acute lymphoblastic leukemia of childhood (T-ALL) in a hypoxic
environment. 4th International Conference on Human Tumor Cloning, January 8-10,
1984, Tucson, Arizona.
8.
*Cohen PS and Smith SD: Differential sensitivity of malignant lymphoid and normal
myeloid colony forming cells (CFU-C) to 1, 10-orthophenanthrolene (OP). 4th
International Conference on Human Tumor Cloning, January 8-10, 1984, Tucson,
Arizona.
9.
*Snodgrass W, Smith SD, Trueworthy R, Vats TS, Klopovich P and Kisker S: Pediatric
clinical pharmacology of 6-mercaptopurine: Lack of compliance as a factor in leukemic
relapse. Proc Am Soc Clinic Oncol 3:C794, 1984.
18
10.
*Snodgrass W, Smith S, Klopovich P, Vats T, Trueworthy R, Kisker S, Melethil S and
Rachmel A: Pediatric clinical pharmacology of 6-mercaptopurine: Drug disposition
variability as a factor in leukemia relapse. FASEB 43:951, 1984.
11.
*Lee PDK, Rosenfield RG, Hintz RL and Smith SD. Receptors for insulin-like growth
factor I, insulin, and growth hormone on human leukemia lymphoblastics. Leukemia
Society of America, 1984.
12.
*Lee PDK, Rosenfield RG, Hintz RL and Smith SD. Receptors for insulin-like growth
factor I, insulin, and growth hormone on human leukemia lymphoblastics. Leukemia
Society of America, 1984.
13.
*Wu N, Jalkanen S, Hsu M, Smith S and Butcher E. Organ-specific lymphocyte
endothelial cell recognition mechanisms expressed by human neoplastic lymphocytes.
FASEB 44:1261, 1985.
14.
*Snodgrass WR, Smith SD, Trueworthy RC, Vats TS, Melethil S. Probable enterohepatic
cycling of 6-mercaptopurine in children. American Society Clinical Pharmacology and
Therapeutics. p54, 1985.
15.
*Cogen PH, Belza MC, Smith S. Long post-operative survival with primary intracranial
sarcoma. Am Assoc Neurolog Surg 1985.
16.
*Belza MG, Cogen PH, Donaldson SS, Smith S and Hanbery JW. A multifactorial
analysis of prognostic factors in the treatment of medulloblastoma. Am Assoc Neurolog
Surg 1986.
17.
*Carroll WL, Link MP, Smith SD, Bologna-Vaughan S, Carswell C and Levy R. Antiidiotype antibodies in childhood B cell leukemia (BL). Pediatric Res 20:227a, 1986.
18.
*Neff J, Lowman J, Vats T, Trueworthy R and Smith S. The effects of intensive
chemotherapy on wound healing and bone graft incorporation in osteosarcoma patients
undergoing limb preservation procedures. Proc Am Soc Clin Oncol 5:265, 1986.
19.
*Morgan R, Smith SD, Morgan S, Bergr C, Jarzabek, V, Hecht BK, Sandberg A, Hecht
F. Constant chromosome 5q35 breakpoint in malignant histiocytosis. Association of
Cytogenetic Technologists, June 1986.
20.
*Smith SD. Cellular response to growth factors. Leukemia 1:269, 1987.
21.
*Rubin CM, LeBeau MM, Smith SD, Rowley JD and Westbrook CA. Philadelphia
chromosome-positive (Ph1+) acute lymphoblastic leukemia (ALL): DNA rearrangements
on chromosomes 9 and 22 identified using pulsed field gel electrophoresis (PFGE).
Blood 68:264a, 1986.
22.
*Molina A, Tung R, Calili N, Donlon T, Smith SD and Sklar J. Multiclonal
lymphoproliferations of B-cell and T-cell lineage in angioimmunoblastic
lymphadenopathy with dysproteinemia (AILD). Blood, 72:225a, 1988.
19
23.
*Smith SD, Winick N, Shuster J, Land V, Rivera GK: Treatment of isolated central
nervous system relapse (CNSR) in children with acute lymphoblastic leukemia (ALL): A
Pediatric Oncology Group Study. ASCO 9:217, 1990.
24.
*Smith SD, Wofford M, Shuster J, Rivera GK: Treatment of testicular leukemia in
children with acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group (POG)
Study. ASCO 9:218, 1990.
25.
*Smith SD, Sadowitz PD, Shuster J, Rivera GK: Treatment of late bone marrow (LBM)
relapses in children with acute lymphoblastic leukemia (ALL): A Pediatric Oncology
Group (POG) Study. AACR 31:201, 1990.
26.
*Molina A, Mcfall P, Galili N, Banga CD, Warnke R, Donlon TA, Sklar J and Smith SD:
Isolation and characterization of an angioimmunoblastic Lymphadenopathy (AILD)related lymphoma cell line. AACR 31:191, 1990.
27.
*Inaba T, Roberts WM, Jolly KW, Shapira LH, Raimondi SC, Smith SD and Look AT:
Molecular cloning of a t(17;19)(q22;p13) chromosomal translocation breakpoint in
lymphoblastic leukemia cells: The E2A gene on chromosome 19 is joined to new
sequences on chromosome 17. Blood 78:169A, 1991.
28.
*Goodell WR, Zhang L, Lorenzana AN, Smith, SD: Inhibitory effects of transforming
growth factor beta on acute lymphoblastic leukemia cell lines. SPR 29:141A, 1991.
29.
*Downie PA, Zhang L. Goodell WR, Goldberg A, McCabe NR, Lu M-M, LeBeau MM,
Smith SD: Monocyte removal improves the establishment of growth factor independent
cell lines from children with B-precursor acute lymphoblastic leukemia (ALL). Blood
80:207a, 1992.
30.
*Nachman J, Lukens J, Gaynon P, Magenis E, Wolff L, Sather H, Trigg M, Smith SD,
Hammond D: Predictors of slow early response (SER) to BFM induction therapy in
children and young adults with acute lymphoblastic leukemia. A report from Childrens
Cancer Group (CCG). Blood 80:257a, 1992.
31.
*Koeppen H, Siegel C, LeMoine P, Moldwin RL, Smith SD: Expression of cytokine
genes by B-cell lineage acute lymphoblastic leukemia cells. Laboratory Investigation,
72:114a, 1995.
32.
*Nachman J, Sather H, Lukens J, Gaynon P, Wolff L, Arthur D, Cherlow J, Trigg, M,
Smith SD: Intrathecal methotrexate is sufficient central nervous system (CNS)
prophylaxis for high risk patients with acute lymphoblastic leukemia (ALL) showing a
rapid early response (RER) to BFM induction chemotherapy. Children’s Cancer Group
(CCG). Blood 86:265a, 1995.
20